These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 24114900)

  • 1. A population pharmacokinetic model of remifentanil in pediatric patients using body-weight-dependent allometric exponents.
    Staschen CM; Mahmood I
    Drug Metabol Drug Interact; 2013; 28(4):231-7. PubMed ID: 24114900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age- and Bodyweight-dependent Allometric Exponent Model for Scaling Clearance and Maintenance Dose of Theophylline From Neonates to Adults.
    Tegenge MA; Mahmood I
    Ther Drug Monit; 2018 Oct; 40(5):635-641. PubMed ID: 30086085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allometric relationships between the pharmacokinetics of propofol in rats, children and adults.
    Knibbe CA; Zuideveld KP; Aarts LP; Kuks PF; Danhof M
    Br J Clin Pharmacol; 2005 Jun; 59(6):705-11. PubMed ID: 15948935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model.
    Peeters MY; Allegaert K; Blussé van Oud-Alblas HJ; Cella M; Tibboel D; Danhof M; Knibbe CA
    Clin Pharmacokinet; 2010 Apr; 49(4):269-75. PubMed ID: 20214410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric models for adult target-controlled infusion pumps.
    Anderson BJ
    Paediatr Anaesth; 2010 Mar; 20(3):223-32. PubMed ID: 19627530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A bodyweight-dependent allometric exponent for scaling clearance across the human life-span.
    Wang C; Peeters MY; Allegaert K; Blussé van Oud-Alblas HJ; Krekels EH; Tibboel D; Danhof M; Knibbe CA
    Pharm Res; 2012 Jun; 29(6):1570-81. PubMed ID: 22287046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Allometric Model of Remifentanil Pharmacokinetics and Pharmacodynamics.
    Eleveld DJ; Proost JH; Vereecke H; Absalom AR; Olofsen E; Vuyk J; Struys MMRF
    Anesthesiology; 2017 Jun; 126(6):1005-1018. PubMed ID: 28509794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of drug clearance in children: impact of allometric exponents, body weight, and age.
    Mahmood I
    Ther Drug Monit; 2007 Jun; 29(3):271-8. PubMed ID: 17529882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic modeling of the hypotensive effect of remifentanil in infants undergoing cranioplasty.
    Standing JF; Hammer GB; Sam WJ; Drover DR
    Paediatr Anaesth; 2010 Jan; 20(1):7-18. PubMed ID: 19825011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.
    Trame MN; Bergstrand M; Karlsson MO; Boos J; Hempel G
    Clin Cancer Res; 2011 Nov; 17(21):6867-77. PubMed ID: 21918171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation.
    Paci A; Vassal G; Moshous D; Dalle JH; Bleyzac N; Neven B; Galambrun C; Kemmel V; Abdi ZD; Broutin S; Pétain A; Nguyen L
    Ther Drug Monit; 2012 Apr; 34(2):198-208. PubMed ID: 22406655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A general purpose pharmacokinetic model for propofol.
    Eleveld DJ; Proost JH; Cortínez LI; Absalom AR; Struys MM
    Anesth Analg; 2014 Jun; 118(6):1221-37. PubMed ID: 24722258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of Drug Clearance in Premature and Mature Neonates, Infants, and Children ≤2 Years of Age: A Comparison of the Predictive Performance of 4 Allometric Models.
    Mahmood I
    J Clin Pharmacol; 2016 Jun; 56(6):733-9. PubMed ID: 26437918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allometric extrapolation of factors VII, VIII and IX clearance in children from adults.
    Mahmood I
    J Thromb Haemost; 2012 Aug; 10(8):1609-13. PubMed ID: 22612736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of ciprofloxacin in pediatric patients.
    Rajagopalan P; Gastonguay MR
    J Clin Pharmacol; 2003 Jul; 43(7):698-710. PubMed ID: 12856383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults.
    Wang C; Allegaert K; Peeters MY; Tibboel D; Danhof M; Knibbe CA
    Br J Clin Pharmacol; 2014 Jan; 77(1):149-59. PubMed ID: 23772816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of drug clearance in children 3 months and younger: an allometric approach.
    Mahmood I
    Drug Metabol Drug Interact; 2010; 25(1-4):25-34. PubMed ID: 21417791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of morphine dose in humans.
    Holford NH; Ma SC; Anderson BJ
    Paediatr Anaesth; 2012 Mar; 22(3):209-22. PubMed ID: 22212108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which model for propofol TCI in children.
    Constant I; Rigouzzo A
    Paediatr Anaesth; 2010 Mar; 20(3):233-9. PubMed ID: 20470319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.